Status:
COMPLETED
Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Pain
Eligibility:
All Genders
17+ years
Phase:
PHASE4
Brief Summary
This study will assess the safety and efficacy of lumiracoxib 400 mg in relieving moderate to severe post-dental surgery pain, compared to both placebo and celecoxib 400 mg.
Eligibility Criteria
Inclusion
- Requiring extraction of two or more partially impacted or fully bony impacted third molars. At least one of the extractions must be mandibular
- Moderate to severe post-dental surgery pain intensity (as rated by the patient on the categorical pain intensity scale within five hours of surgery
Exclusion
- Evidence or history of any cardiac and cerebral thrombotic/ ischemic diseases and/ or events
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
364 Patients enrolled
Trial Details
Trial ID
NCT00348491
Start Date
February 1 2006
Last Update
February 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dental Research Clinic
Austin, Texas, United States, 78703